

Table of Contents

CERTIFICATE	i
DECLARATION BY THE CANDIDATE.....	ii
COPYRIGHT TRANSFER CERTIFICATE.....	iii
Acknowledgement.....	iv
Table of Contents	vi
List of Tables.....	xi
List of Figures	xiii
List of Abbreviations.....	xviii
List of Symbols	xx
Preface	xxii
Chapter 1 Introduction	1
1.1 Neurodegeneration.....	2
1.2 Parkinson’s disease.....	3
1.3 Amyotrophic lateral sclerosis	3
1.4 Huntington’s disease.....	4
1.5 Spinocerebellar ataxia.....	4
1.6 Spinal muscular atrophy	5
1.7 Dementia.....	5
1.7.1 Frontotemporal dementia	5

1.7.2 Dementia with Lewy bodies and Parkinson’s Dementia.....	6
1.7.3 Alzheimer’s disease.....	7
Chapter 2 Literature Review	13
2.1 The cholinesterase enzymes	14
2.2 Matrix Metalloproteinases.....	15
2.3 BACE-1	17
2.4 PDE-9A	19
2.5 Multi-target directed ligands (MTDLs).....	20
2.5.1 Development of MTDLs	21
2.5.2 Rational combination of multiple targets for MTDLs.....	21
2.5.3 MTDL lead generation	22
2.5.4 MTDL lead optimization.....	25
Chapter 3 Rationale, Objectives and Plan of Work	27
3.1 Rationale and Objective.....	28
3.2 Plan of study	29
Chapter 4 Multifunctional hybrid sulfonamides as novel therapeutic agents for Alzheimer’s disease	31
4.1 Introduction	32
4.2 Materials and methods.....	34
4.2.1 Rationale of drug design & in-silico optimization	34
4.2.2 Virtual screening of commercial and non-commercial databases.....	34
4.2.3 Extra precision molecular docking.....	37

4.2.4 Chemistry	37
4.2.5 Scheme I- Synthesis of p-substituted benzene alkanolic amide derivatives	38
4.2.6 Biology	50
4.2.7 In silico studies	57
4.3 Results & discussions	58
4.3.1 Rational of drug design and discovery	58
4.3.2 Chemistry	60
4.3.3 Biological Evaluation	61
4.3.4 In-silico studies.....	72
4.4 Conclusions	77
 Chapter 5 Combined ligand-based and structure-based design of anti-Alzheimer agents targeting Phosphodiesterase 9A	
5.1 Introduction	80
5.2 Materials and methods.....	82
5.2.1 Selection of protein structure	82
5.2.2 Pharmacophore Modeling	83
5.2.3 Molecular properties filter.....	83
5.2.4 Pan-assay interference compounds (PAINS) filter	84
5.2.5 Protein Preparation	84
5.2.6 Ligand Preparation	84
5.2.7 Grid generation for molecular docking	85
5.2.8 Virtual screening and molecular docking.....	85

5.2.9 ADMET property	86
5.2.10 Molecular dynamics	87
5.3 Results & discussions	88
5.3.1 Pharmacophore modeling and virtual screening	88
5.3.2 Drug likeliness and molecular properties filter	89
5.3.3 Pan-assay interference compounds (PAINS) filter	92
5.3.4 Protein and ligand preparation.....	93
5.3.5 Grid generation for molecular docking	94
5.3.6 Virtual screening and molecular docking.....	94
5.3.7 ADMET properties.....	100
5.3.8 Molecular dynamics simulation studies	102
5.4 Conclusion.....	111
Chapter 6 Identification of novel multi-target N-benzyl piperazinyl sulfonamide derivatives for the management of AD.....	112
6.1 Introduction	113
6.2 Materials and methods.....	114
6.2.1 Pharmacophore development and virtual screening.....	114
6.2.2 Molecular docking.....	115
6.2.3 Chemistry	117
6.2.4 Biology	126
6.2.5 Molecular dynamics & simulation	133
6.3 Results & discussions	135

6.3.1 Pharmacophore development and virtual screening.....	135
6.3.2 Molecular docking.....	136
6.3.3 Chemistry	139
6.3.4 Biological Evaluation	141
6.3.5 In-vitro blood-brain barrier permeation assay (PAMPA)	146
6.3.6 Propidium iodide displacement assay	147
6.3.7 Scopolamine induced amnesia model	148
6.3.8 BACE1 activity assay.....	153
6.3.9 Molecular dynamics simulations.....	154
6.4 Conclusions	157
Chapter 7 Summary and Conclusions	161
7.1 Summary and Conclusions	162
Chapter 8 References	167
References	168